Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tobemstomig - Hoffmann-La Roche

Next Previous
Drug Profile

Tobemstomig - Hoffmann-La Roche

Alternative Names: Anti PD-1 anti LAG-3 bispecific antibody - Roche; Anti PD1 x LAG3; anti-PD-1/Anti-LAG-3 bispecific antibody RO7247669; anti-PD1/anti-LAG3 bispecific antibody RO7247669; PD1-LAG3 BsAb; RG-6139; RO-7247669

Latest Information Update: 26 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer

Most Recent Events

  • 26 Dec 2025 Discontinued - Phase-I/II for Liver cancer (Neoadjuvant therapy, Combination therapy) in Austria, France, Germany, New Zealand, South Korea, Spain, Spain, Taiwan, United Kingdom (IV)
  • 13 Nov 2025 Hoffmann-La Roche completes a phase I/II trial in Liver cancer (Combination therapy, Neoadjuvant therapy) in USA, Austria, France, Germany, New Zealand, South Korea, Spain, Taiwan, United Kingdom (IV) (NCT05908786)
  • 08 Nov 2024 Discontinued - Phase-I for Solid tumours in Japan (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top